Matthew Davids, MD, MMSc
@drmdavids.bsky.social
Hematologist/oncologist, translational CLL investigator, director of lymphoma clinical research @dana-farber, faculty @harvard med. posts are my own & not medical advice
Excited to be opening this trial soon @danafarber.bsky.social and several other sites around the globe!
It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
September 24, 2025 at 3:14 PM
Excited to be opening this trial soon @danafarber.bsky.social and several other sites around the globe!
Nir Hacohen from @broadinstitute.org and @massgeneralbrigham.bsky.social kicking off the 3rd annual Intercepting Blood Cancers meeting in Nice! @ireneghobrial.bsky.social
March 13, 2025 at 1:23 PM
Nir Hacohen from @broadinstitute.org and @massgeneralbrigham.bsky.social kicking off the 3rd annual Intercepting Blood Cancers meeting in Nice! @ireneghobrial.bsky.social